EMEA-001169-PIP01-11-M05

Key facts

Invented name
Praluent
Active substance
Alirocumab
Therapeutic area
Endocrinology-Gynaecology-Fertility-Metabolism
Decision number
P/0550/2021
PIP number
EMEA-001169-PIP01-11-M05
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of elevated cholesterol
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Sanofi-Aventis Recherche & Développement 

Tel. +33 169745695
E-mail: contact-us@sanofi.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating
Average
1 rating